19 24

Cited 0 times in

Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure

Authors
 Jaewoong Kim  ;  Jin Won Chang  ;  Jun Yong Park 
Citation
 Journal of Liver Cancer (대한간암학회지), Vol.20(1) : 72-77, 2020-03 
Journal Title
 Journal of Liver Cancer (대한간암학회지) 
ISSN
 2288-8128 
Issue Date
2020-03
Keywords
Hepatocellular carcinoma ; Lung metastasis ; Sorafenib failure ; Immunotherapy ; Nivolumab
Abstract
Over the past decade, standard first-line systemic treatment of advanced hepatocellular carcinoma (HCC) has been based on sorafenib, a multi-kinase inhibitor. Regorafenib, another tyrosine kinase inhibitor, is the only second-line therapy that has been globally approved after progression under sorafenib treatment. Recently, immunotherapeutic agents have emerged as promising treatment options in many different malignancies, including advanced HCC. Nivolumab is the first immunotherapy approved by the Food and Drug Administration for use in HCC patients with advanced-stage second-line after sorafenib failure. In this report, a case of advanced HCC with multiple lung metastases in which a complete response and maintained progression-free status was achieved with nivolumab, following the failure of transarterial chemoembolization and sorafenib is presented. We hope this report may help expand the clinical application of second-line treatment.
Files in This Item:
T202001446.pdf Download
DOI
10.17998/jlc.20.1.72
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/176159
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links